Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
pegylated liposomal doxorubicin · 1 trial · 3 indications
Comparison of duration of survival between the 2 treatment groups
| Arm | Type | Description |
|---|---|---|
| PLD 40 mg/m2 plus VTX-2337 | EXPERIMENTAL | The dosing schedule will be be based on a 28-day cycle. The starting dose schedule is PLD on Day 1 plus VTX-2337 on Day 3, Day 10, and Day 17 for the first 4 cycles. Starting with cycle 5, the dose regimen will be PLD on Day 1 plus VTX-2337 on Day 3 only, without additional doses of VTX-2337 on Days 10 and Day 17. |
| PLD 40 mg/m2 plus placebo | ACTIVE_COMPARATOR | The dosing schedule will be based on a 28-day cycle. The starting dose schedule is PLD on Day 1 plus placebo on Day 3, Day 10, and Day 17 for the first 4 cycles. Starting with cycle 5, the dose regimen will be PLD on Day 1 plus placebo on Day 3 only. |
| Name | Type | Description |
|---|---|---|
| pegylated liposomal doxorubicin (PLD) | DRUG | - |
| VTX-2337 | DRUG | TLR8 Agonist |
| Placebo | DRUG | - |
Inclusion Criteria: 1. Patients must have recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. 2. Patients with the following histologic cell types are eligible: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated car...
Pegylated liposomal doxorubicin is used for the treatment of recurrent or persistent epithelial ovarian cancer, as well as fallopian tube cancer and primary peritoneal cancer. It is being studied in a Phase 2 clinical trial for these conditions.
Pegylated liposomal doxorubicin is developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY on the stock market.
Pegylated liposomal doxorubicin is in Phase 2 clinical development for epithelial ovarian cancer. It is an investigational drug and has not yet been approved by regulatory authorities.
Pegylated liposomal doxorubicin is being studied in clinical trial NCT01666444, titled "VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer." This Phase 2 trial has been completed and enrolled 297 female participants aged 18 years and older in the United States.
Yes, pegylated liposomal doxorubicin is classified as a small molecule drug. It is being investigated in the oncology therapeutic area for the treatment of epithelial ovarian cancer.